Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins

Metabolism: Clinical and Experimental

Volumn 50, Issue 1, 2001, Pages 112-119

  Marcoux, Caroline ^a   Tremblay, Michel ^a   Fredenrich, Alexandre ^a   Davignon, Jean ^a   Cohn, Jeffrey S ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIPOGENESIS; LIPOLYSIS; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIPOPROTEIN SYNTHESIS; METABOLIC BALANCE; PRIORITY JOURNAL; RISK FACTOR;

EID: 0035182392     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1053/meta.2001.19452     Document Type: Article

References (41)

1. Inhibition of lipoprotein lipase by an apolipoprotein of human very low density lipoprotein
2. Further observations on the activation and inhibition of lipoprotein lipase by apolipoproteins
3. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III
4. Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by perfused rat liver
5. Opposing effects of apolipoprotein E and C on lipoprotein binding to the low density lipoprotein receptor-related protein
6. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway
7. Apolipoprotein C-II and C-III levels in hyperlipoproteinemia
8. Quantitative determination of human apolipoprotein C-III by electroimmunoassay
9. Plasma lipoprotein distribution of apoC-III in normolipidemic and hyperlipidemic subjects: Comparison of the apoC-III to apoE ratio in different lipoprotein fractions
10. Effect of heparin-induced lipolysis on the distribution of apolipoprotein E among lipoprotein subclasses. Studies with patients deficient in hepatic triglyceride lipase and lipoprotein lipase
11. The metabolism of very low density lipoprotein proteins. II. Studies on the transfer of apolipoproteins between plasma lipoproteins
12. David Rubinstein Memorial Lecture: The biochemical and clinical significance of the interrelationship between very low density and high density lipoproteins
13. Hypertriglyceridemia: Changes in the plasma lipoprotein associated with an increased risk of cardiovascular disease
14. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts
15. Coronary angiographic changes with lovastatin therapy: The Monitored Atherosclerosis Regression Study (MARS)
16. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts: Lipid and nonlipid factors
17. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin
18. Beneficial effects of colestipol-niacin therapy on the common carotid artery: Two- and four-year reduction of intima-media thickness measured by ultrasound
19. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy
20. Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins
21. The familial hyperlipoproteinemias
22. Plasma concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic and hyperlipidemic subjects
23. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apoB-100 and anti apo A-I immunoaffinity mixed gels
24. Characterization of remnant-like particles isolated by immunoaffinity gel from the plasma of type III and type IV hyperlipoproteinemic patients
25. A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol
26. Improved phenotyping of apolipoprotein E: Application to population frequency distribution
27. Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: The ECTIM Study
28. Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects
29. Interaction of LpB, LpB:E, LpB:C-III, and LpB:C-III:E lipoproteins with the low density lipoprotein receptor of HeLa cells
30. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E
31. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apoC-III and reduced apoE on the particles
32. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E
33. Plasma remnant-like particle lipid and apolipoprotein levels in normolipidemic and hyperlipidemic subjects
34. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events
35. Serum lipid and lipoprotein levels in Japanese patients with familial hypercholesterolemia
36. Prevalence of double pre-beta lipoproteinemia in hyperlipidemic patients is influenced by gender, menopausal status, and apoE phenotype
37. Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III and type IV hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemfibrozil
38. Changing relative proportions of apolipoproteins CII and CIII of very low density lipoproteins in hypertriglyceridemia
39. Apoprotein composition of very low density lipoproteins of human serum
40. Evidence for non-equilibrating pools of apolipoprotein C-III in plasma lipoproteins
41. Abnormal activation of lipoprotein lipase by non-equilibrating apoC-II: Further evidence for the presence of non-equilibrating pools of apolipoproteins C-II and C-III in plasma lipoproteins